Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Blood (2024) 144 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2024-201086

Published: 2024

Journal Articles

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Charlotte Pawlyn, Faith E Davies, Gordon Cook, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Catherine Olivier, Anna Hockaday, John R Jones, Martin F Kaiser, Matthew W. Jenner, Walter Martin Gregory, Ruth M de Tute, Roger G Owen, Mark Drayson, David A. Cairns, Gareth Morgan, Graham Jackson

Blood (2024) 144 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2024-205788

Published: 2024

Journal Articles

Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Blood (2024) 144 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2024-201448

Published: 2024

Journal Articles

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Graham Jackson, Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, David A. Cairns, Gareth Morgan

Blood (2024) 144 (Supplement 1): 3375.

https://doi.org/10.1182/blood-2024-205871

Published: 2024

Journal Articles

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Blood (2024) 144 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2024-209772

Published: 2024

Journal Articles

Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Blood (2024) 144 (Supplement 1): 898.

https://doi.org/10.1182/blood-2024-193310

Published: 2024

Journal Articles

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, Gareth Morgan, David A. Cairns, Graham Jackson

Blood (2024) 144 (Supplement 1): 771.

https://doi.org/10.1182/blood-2024-208255

Published: 2024

Journal Articles

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Blood (2024) 144 (Supplement 1): 673.

https://doi.org/10.1182/blood-2024-209653

Published: 2024

Journal Articles

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Blood (2024) 144 (Supplement 1): 385.

https://doi.org/10.1182/blood-2024-209720

Published: 2024

Journal Articles

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Martin F. Kaiser, Rachel Phillip, Andrew Hall, Amy Holroyd, Laura Bevington, Ruth M de Tute, Laura Clayton, Sadie Roberts, Graham Jackson, Gordon Cook, Richard S Houlston, Mark Drayson, Roger Owen, Guy Pratt, Sarah R Brown, Matthew W. Jenner

Blood (2023) 142 (Supplement 1): 881.

https://doi.org/10.1182/blood-2023-177896

Published: 2023

Journal Articles

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Blood (2023) 142 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2023-188697

Published: 2023

Journal Articles

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Blood (2023) 142 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2023-188844

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Blood (2023) 142 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2023-187202

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Blood (2023) 142 (Supplement 1): 4710.

https://doi.org/10.1182/blood-2023-187453

Published: 2023

Journal Articles

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Molly Reed, David Allan Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Roger Owen, Kevin Boyd, Gordon Cook, Gareth J. Morgan, Graham Jackson, Mark Drayson, John R Jones

Blood (2023) 142 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2023-181939

Published: 2023

Journal Articles

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Blood (2023) 142 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2023-188672

Published: 2023

Journal Articles

Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study

Frances Seymour, Claire Taylor, Sharon Gilson, Catherine Olivier, Christopher Parrish, David Allan Cairns, Christopher Winder, Matt Clark, Lesley Smith, Andrew Scarsbrook, Charlotte Pawlyn, Graham Jackson, Gordon Cook

Blood (2023) 142 (Supplement 1): 6602.

https://doi.org/10.1182/blood-2023-184553

Published: 2023

Journal Articles

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Aikaterini Panopoulou, David A. Cairns, Amy Holroyd, Isabel Nichols, Nikita Cray, Charlotte Pawlyn, Gordon Cook, Mark Drayson, Kevin Boyd, Faith E. Davies, Matthew Jenner, Gareth J. Morgan, Roger Owen, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2023) 141 (14): 1666–1674.

https://doi.org/10.1182/blood.2022018339

Published: 2023

Includes: Supplemental data

Journal Articles

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Kushani Ediriwickrema, Neil K Rabin, Shirley D'Sa, Graham Jackson, Peter Hoskin, Eve Gallop-Evans, Patricia Diez, Catherine Parbutt, Andre Lopes, Sevasti Galani, Laura Clifton-Hadley, Darren Edwards, Husne Timur Tezver, Ruth M. de Tute, Andrew Bates, Roger G Owen

Blood (2022) 140 (Supplement 1): 12626–12627.

https://doi.org/10.1182/blood-2022-158528

Published: 2022

Journal Articles

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Martin F. Kaiser, Pieter Sonneveld, David Cairns, Marc S Raab, Alessandra Larocca, Sarah R Brown, Marc-A. Baertsch, Cong Li, Pellegrino Musto, Kwee Yong, Elias K Mai, Andrea Capra, Gordon Cook, Hartmut Goldschmidt, Mario Boccadoro, Graham Jackson, Niels Weinhold, Francesca Gay

Blood (2022) 140 (Supplement 1): 1556–1558.

https://doi.org/10.1182/blood-2022-160130

Published: 2022

NARROW

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial

Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only